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Recommended by Catherine Dinauer
The choice of therapeutic strategies for hyperthyroidism during pregnancy is limited. Surgery and radioiodine are typically
avoided, leaving propylthiouracil and methimazole in the US. Carbimazole, a metabolic precursor of methimazole, is available
in some countries outside of the US. In the US propylthiouracil is recommended because of concern about developmental toxicity
from methimazole and carbimazole. Despite this recommendation, the data on developmental toxicity of all three agents are
extremely limited and insuﬃcient to support a policy given the broad use of methimazole and carbimazole around the world. In
the absence of new human or animal data we describe the development of a new structure-activity relationship (SAR) model for
developmentaltoxicityusingthecat-SARexpertsystem.TheSARmodelwasdevelopedfromdatafor323compoundsevaluatedfor
human developmental toxicity with 130 categorized as developmental toxicants and 193 as nontoxicants. Model cross-validation
yielded a concordance between observed and predicted results between 79% to 81%. Based on this model, propylthiouracil,
methimazole, and carbimazole were observed to share some structural features relating to human developmental toxicity. Thus
given the need to treat women with Graves’s disease during pregnancy, new molecules with minimized risk for developmental
toxicity are needed. To help meet this challenge, the cat-SAR method would be a useful in screening new drug candidates for
developmental toxicity as well as for investigating their mechanism of action.
Copyright © 2009 Albert R. Cunningham et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hyperthyroidism occurs in approximately 2/1000 preg-
nancies with the majority of those cases being Graves’
disease [1], an autoimmune disorder caused by TSH-
receptor stimulating autoantibodies. Propylthiouracil (PTU)
is the primary treatment of hyperthyroidism in the US
followed by methimazole (MMI) while carbimazole (CMI)
is not distributed in the US. Surgery and radioiodine are
not recommended treatment modalities during pregnancy.
Untreated hyperthyroidism during pregnancy leads to devel-
opmental toxicity which includes spontaneous abortion,
prematurity, growth restriction, and fetal death [1, 2]. It
is not clear if untreated hyperthyroidism during pregnancy
leads to structural malformations [3, 4]; however one
dataset suggested that the risk of malformations was greater
than expected among infants from untreated than treated
pregnancies [5]. Additionally, there is concern that one of
the medical therapeutic strategies, MMI, may be a weak
developmentaltoxicant,producingstructuralmalformations
[6], as well as fetal goiter. Part of this concern stems from the
observation that CMI is a weak developmental toxicant and
one of its metabolites is MMI.
On the one hand, as just mentioned, treatment of
hyperthyroidism during pregnancy may result in devel-
opmental toxicity, as the available drugs cross the pla-
centa and can cause fetal goiter. On the other hand,
while the data remain unclear, there is evidence suggesting
that maternal hypothyroidism is associated with impaired
fetal neurodevelopment. Consequently the clinician must
balance the use of the antithyroid medications against
the potential developmental consequences of inadequate
or aggressive therapy, with a limited set of therapeutic
options.2 International Journal of Pediatric Endocrinology
Several assumptions about PTU and MMI have guided
the medical treatment strategies for Graves’ disease during
pregnancy in the US [2, 6–8]. It has been assumed that
placental transport of PTU is less than MMI, it has been
assumed that fetal and neonatal thyroid eﬀects of PTU is
less than with MMI (based on lower placental transport),
it has been assumed that MMI exposure during pregnancy
leads to greater impairment of neurocognitive development
than with PTU exposure, and it has been assumed that
MMI produces structural defects and that PTU does not.
A thoughtful review and analysis of literature by Mandel
has demonstrated that these assumptions are not correct
[2, 6].
Given the uncommon nature of Graves’ disease in preg-
nancyandtheweaklinkbetweentheantithyroidmedications
and malformations, we have taken a diﬀerent approach
to assess the potential developmental toxicity of the drugs
whicharebeingusedtotreatthediseaseinpregnancy.Several
years ago we created datasets to evaluate the structural
determinants of developmental toxicity in experimental
animals and humans [9–13]. Statistical analyses demon-
strated that animal models are reasonable predictors of
human developmental toxicity [14], and that rules could
be agreed upon among experts in developmental toxicity
for evaluating animal and human data [9]. Subsequently we
evaluated the utility of structure-activity relationship (SAR)
models generated by MultiCASE for studying and predicting
developmental toxicity in diverse species including humans
[12]. This later dataset of chemicals assessed for human
developmental toxicity has subsequently been utilized to
create a more transparent and robust model of develop-
mental toxicity using the categorical-SAR (cat-SAR) expert
system.
Brieﬂy, the cat-SAR expert system diverges from other
SAR expert systems wherein there is a high degree of user
ﬂexibility in both learning set development and model
parameterization [15]. Cat-SAR analysis allows the user to
specifyadjustablemodelingattributesincludingtheselection
of size of the 2-dimensional fragments, whether or not
to include hydrogen atoms in the analysis, and rules for
identifying important fragments for the ﬁnal model. Hence,
the selection of compounds included in the learning set and
control over various model attributes provides the user with
the ability to rigorously explore the relationships between
chemical structure and biological activity. Application of the
cat-SAR expert system to a toxicological or pharmacological
endpoint is thus not constrained wherein a given set of data
must ﬁt the attributes of a predeﬁned and often proprietary
modeling process.
2. Methods
2.1. Human Developmental Toxicity Dataset. Data on human
developmental toxicity were derived from the teratogen
information system and a database that utilized the US FDA
guidelines as described previously [12]. Thechemicalsin this
database were speciﬁcally characterized with respect to risk
for human developmental toxicity including death, growth
retardation and functional and structural abnormalities.
2.2. Cat-SAR Structure Activity Relationship Expert System.
The cat-SAR approach is a computational SAR or in silico
toxicity analysis and prediction “expert system.” In previous
analyses, the cat-SAR program was able to achieve an overall
concordance between observed and predicted values of 92%
for a set of chemicals assessed for their ability to induce
respiratory hypersensitivity [16], 80%–90% for a set of
environmental estrogen mimics [17], and 78%–84% for a set
of rat mammary carcinogens [15].
Cat-SAR models are built through a comparison of
structural features found amongst categorized compounds
in the model’s learning set. Generically, these categories are
toxicologically active and inactive compounds. Essentially,
the cat-SAR approach is transparent in the development of
the learning set, the identiﬁcation of fragments, and the
determination of signiﬁcant or important ones. Moreover,
the approach allows user intervention and model optimiza-
tion throughoutthemodeling process. This method includes
theabilitytoexaminetheentirefragmentbaseandtoexplore
and optimize the fragments that have perceived biological
relevance.
Moreover, since cat-SAR analyzes categorical data and
2-dimensional fragments rather than intact chemicals, the
program can examine noncongeneric datasets that are
divided into categories of activity rather than degrees
of potency as in the case of quantitative SAR (QSAR).
Thus, unlike Hansch and conformational molecular ﬁeld
analysis (CoMFA) approaches that require continuous-type
data, cat-SAR works by identifying molecular attributes
associated with biological activity by comparing attributes
of active (e.g., teratogenic) to inactive (e.g., nonteratogenic)
compounds. The models and subsequent predictions based
on this dichotomy can then be used to examine struc-
tural features associated with teratogenicity and predict the
likelihood of teratogenic activity of unknown compounds,
respectively.
Overall, the cat-SAR models discussed herein for devel-
opmental toxicity demonstrate a high degree of predictivity
and mechanistically interpretability and can be useful for
screening new drug candidates for developmental toxicity
as well as for investigating their therapeutic and toxic
mechanisms of action.
2.2.1. Learning Set Development. The cat-SAR models
are built through a comparison of structural features
found amongst two designated categories of compounds
in the model’s learning set. As mentioned, for these
analyses the categories were developmental-toxicity and
nondevelopmental-toxicity. The cat-SAR learning set con-
sists of the chemical name, its structure as a MOL2 ﬁle, and
its categorical designation (e.g., one or zero for active and
inactive). Typically, organic salts are included as the freebase
and simple mixtures and technical grade preparations may
be included as the major or active component, metals,
metalo-organic compounds and polymers, and mixtures of
unknown composition are not included.
2.2.2. In Silico Chemical Fragmentation and the Compound-
Fragment Data Matrix. Using the Tripos Sybyl HQSARInternational Journal of Pediatric Endocrinology 3
module, each chemical was fragmented in silico into all
possible fragments meeting user-speciﬁed criteria. HQSAR
allows the user to select attributes for fragment determina-
tion including atom counts (i.e., the size of the fragments),
bond types, atomic connections (i.e., the arrangement of
atoms in the fragment), explicit hydrogen atoms, chirality,
and hydrogen bond donor and acceptor groups. Fragments
can be linear, branched, or cyclic moieties. For analysis of
the developmental toxicity dataset the models developed
contained fragments between three and seven atoms in size
and considered atoms, bond types, and atomic connections.
Upon completion of the fragmentation routine a Sybyl
HQSAR add-on is used to produce a compound-fragment
data matrix. In the matrix, the rows are intact chemicals
and columns are the molecular fragments. Thus for each
chemical, a tabulation of all its fragments is recorded across
the table rows and for each fragment all chemicals that
contain it are tabulated down the columns.
The HQSAR module is not used for statistical analysis
or model development. Rather, the compound-fragment
matrix is subsequently analyzed with the cat-SAR expert
system in order to identify structural features associated with
the categorized active and inactive compounds. The cat-
SAR program, human developmental toxicity database, and
the compound-fragments matrix are available through the
corresponding author.
2.2.3. Identifying “Important” Fragments of Activity and
Inactivity. A measure of each fragment’s association with
biological activity is next determined. To ascertain an
association between chemical descriptors (i.e., fragments)
and a chemical’s activity (or inactivity), a set of rules is used
to choose “important” from “unimportant” descriptors.
The ﬁrst selection rule (the Number Rule) is the number
of chemicals identiﬁed in the learning set that possesses
each particular fragment. The second selection rule (the
Proportion Rule) is the proportion of active or inactive
chemicals that then possesses the particular fragment.
Although previously published cat-SAR models required the
user to select speciﬁc values for the Number and Proportion
Rules, a new routine was implemented here to determine
optimal values for the Number and Proportion rules. For
this exercise the values for the Number Rule were allowed
to range between one and eight and the initial values for
the Proportion Rule were allowed to range between 0.50 and
0.95.
2.2.4. Predicting Activity. The resulting list of important
fragments can then be used for mechanistic analysis, or to
predict the activity of an unknown compound. In the latter
circumstance, the model determines which, if any, fragments
from the model’s learning set the test compound contains.
If none are present, no prediction of activity is made for
the compound (i.e., no default prediction). If one or more
fragments are present, the number of active and inactive
compounds containing each fragment is determined. Here
the fragment sum (FragSum) method calculates the average
probability of the active and inactive fragments contained in
a compound and is weighted to the number of active and
inactive compounds that go into deriving each fragment. For
example, if a compound contains two fragments, one being
found in 9/10 active compounds in the learning set (90%
active) and the other being found in 3/3 inactive compounds
(0% active), the unknown compound will be predicted to
be have a probability of activity of 69% (9/10 actives + 0/3
actives = 9/13 actives or 69% chance of activity).
As described, a Cat-SAR prediction of activity or inac-
tivity is based on two separate fragment sets (i.e., the active
fragments and the inactive ones) and the predicted activity
of a chemical is based on the average probability of all the
active and inactive compounds contributing to its structure.
Therefore,toclassifycompoundsbacktoanactiveorinactive
category (i.e., rather than a probability of activity), the
programidentiﬁesanoptimalcutoﬀpointthatbestseparates
the prediction of active and inactive compounds based on
the probabilistic values of activity derived from a model
validation analysis [18]. Depending on the application of the
model, the cutoﬀ point that separates active from inactive
categorization, for example can be adjusted wherein a model
with the best overall concordancecan be selected (i.e.,a most
predictive model), one with equal sensitivity and speciﬁcity
(i.e., a balanced model that does not overly predictive active
compounds at the cost of wrongly predicting inactive one
and viceversa), or one with high sensitivity (i.e., a risk averse
model).
2.3. Model Validation. A self-ﬁt, leave-one-out (LOO), and
multiple leave-many-out (LMO) cross-validations were con-
ducted for each model (see Table 1). For the self-ﬁt, a
model was developed from the complete learning set of 323
compounds and that model was used to predict the activity
of each compound in the learning set to determine the
general robustness of the model. For the LOO validation,
each chemical, one at a time, was removed from the
model’s total fragment set, and an n-1 model was derived.
The activity of the removed chemical was then predicted
using the n-1 model. Predicted vs. experimental values for
each chemical were then compared and the model’s overall
concordance, sensitivity, and speciﬁcity were determined,
where,
Concordance =
Correct predictions
Total predictions
,
Sensitivity =
Correct positive predictions
Total positive predictions
,
Speciﬁcity =
Correct negative predictions
Total negative predictions
.
(1)
For the LMO validation, randomly selected sets of 5%
of the chemicals were removed from the model, and the n-
5% model was derived for each set. The activity of each
of the removed chemicals was then predicted using the n-
5% model. Predicted versus experimental values for the
chemicals in the left out sets were then compared and the
n-5% model’s concordance, sensitivity, and speciﬁcity were
determined. This was repeated 10000 times to compute the
model’s average concordance, sensitivity, and speciﬁcity.4 International Journal of Pediatric Endocrinology
Table 1: Fragment summary, self-ﬁt, and cross validation results
for the developmental toxicity SAR models.
Model 1∗ Model 2∗∗
Fragments
Total 26401 26401
Model 4522 3440
Active 1815 1027
Inactive 2707 2413
Self-ﬁt
Sensitivity 94%
(107/114)
98%
(94/96)
Speciﬁcity 94%
(176/177)
100%
(156/156)
Concordance 94%
(274/291)
99%
(250/252)
Leave-one-out
Sensitivity 78%
(90/115)
75%
(78/104)
Speciﬁcity 79%
(141/179)
85%
(137/162)
Concordance 79%
(231/294)
81%
(215/266)
Leave-many-out
Sensitivity 78%
(4.3/5.5)
74%
(3.7/5.0)
Speciﬁcity 79%
(6.8/8.7)
84%
(6.6/7.9)
Concordance 78%
(11.0/14.2)
80%
(10.3/12.9)
∗Model 1: Balanced sensitivity and speciﬁcity.
∗∗Model 2: Best Concordance.
3. Results andDiscussion
3.1. Model Analysis and Validation. Together, two cat-SAR
developmental toxicity models were produced. Model 1 was
designed to have near-equal sensitivity and speciﬁcity while
Model 2 was designed to demonstrate the best overall con-
cordance between observed and predicted values (Table 1).
Overall, 26 401 unique chemical fragments between 3–7
nonhydrogen atoms were derived for the developmental
toxicity database (Table 1). Of these, for Model 1, 1815
were associated with developmental toxicants and 2707
with nontoxicants (4522 total signiﬁcant fragments). And
for Model 2, 1027 were associated with developmental
toxicants and 2413 with nontoxicants (3440 total signiﬁcant
fragments).
The self-ﬁt analysis yielded concordance between
observed and predicted results of 94% (274/291) for
the balanced sensitivity and speciﬁcity model (Model
1) and 99% (250/252) for the best concordance model
(Model 2). These high concordance rates indicate a robust
model wherein there is suﬃcient structural information
contained in the learning set to distinguish between
active and inactive compounds. The LOO cross-validation
yielded a concordance of 79% for the balanced sensitivity
and speciﬁcity model (Model 1) and 81% for the best
concordance one (Model 2). The LMO cross-validation
yielded an average concordance of 78% for the balanced
sensitivity and speciﬁcity model (Model 1) and 80% for the
best concordance one (Model 2). Overall, since the LOO
and LMO validation results are in near agreement, it is
estimated that the cat-SAR developmental toxicity model is
∼80%, accurate for predicting the developmental toxicity
potential of chemicals not included in the model’s learning
set.
In order to better judge how well these two models
performed in general, one can consider the “accuracy” or
reproducibility of a standard in vitro toxicological test.
For instance, the US National Toxicology Program’s (NTP)
Salmonella mutagenicity database, which is derived from
a standardized protocol, has been estimated to be about
85% reproducible (49). Based on these ﬁndings wherein
the concordance between observed and predicted values for
human developmental toxicity is ∼80% the cat-SAR human
developmentalto xicitymodelsthusappeartobeaspredictive
as data used to develop SAR models from standardized in
vitro assays.
3.2. Analysis of Propylthiouracil, Methimazole, and Car-
bimazole. For these analyses, the balanced sensitivity and
speciﬁcity model (Model 1) was used for analysis of PTU,
MMI, and CMI. This model identiﬁed 13 fragments within
the three antithyroid medications relating to developmental
toxicity (Figure 1). Nine of the 13 fragments were considered
to be associated with developmental toxicants and 4 of the
13 fragments were considered to be associated with non-
developmental toxicants.
Fragments 2184, 2182, and 6241 are found in ﬂuo-
rouracil, for which there is a small amount of human
data on developmental toxicity. However the compound
is known to interfere with DNA synthesis and has been
shown to be a developmental toxicant in rat, mouse, rabbit,
hamster, guinea pig, and in nonhuman primates ([19],
TERIS MicroMedex accessed 06 July 2009).
Fragments 2184, 2182, and 6229 are found in a series of
barbiturates used as sedative-hypnotics and anticonvulsants.
Literature on the developmental toxicity of the sedative-
hypnotics compounds is contradictory [19]. Amobarbital
has been associated in several human studies with cardiovas-
cular malformations although no experimental animal stud-
i e sa p p e a rt oh a v eb e e nc o n d u c t e d[ 19]. Phenobarbital use
throughoutpregnancy,asananticonvulsant,hasbeenassoci-
atedwithfacialandcardiovascularmalformationsinhumans
and experimental animals (TERIS MicroMedex accessed 06
July 2009). Mephobarbital is metabolized to phenobarbital
and has been associated with increased risk of facial malfor-
mations (TERIS MicroMedex accessed 06 July 2009). There
is little animal and human data on metharbital, used as an
anticonvulsant, or on butalbital used as a sedative hypnotic.
Fragments 6172 and 6206 are found in thioguanine
used as an antineoplastic and in treatment of Crohn’s
disease. Thioguanine has been demonstrated to produce
malformations in experimental animals and in humans
([19], TERIS MicroMedex accessed 06 July 2009).International Journal of Pediatric Endocrinology 5
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Frag 9479 (7/8)
Propylthiouracil (+)
Chlorotetracycline (+)
Clomocycline (+)
Demeclocycline (−)
Doxyclycine (+)
Methacycline (+)
Minocycline (+)
Oxytetracycline (+)
Tetracylcine (+)
Frag 9564 (7/8)
Propylthiouracil (+)
Chlorotetracycline (+)
Clomocycline (+)
Demeclocycline (−)
Doxyclycine (+)
Methacycline (+)
Minocycline (+)
Oxytetracycline (+)
Tetracylcine (+)
Frag 9565 (7/8)
Propylthiouracil (+)
Chlorotetracycline (+)
Clomocycline (+)
Demeclocycline (−)
Doxyclycine (+)
Methacycline (+)
Minocycline (+)
Oxytetracycline (+)
Frag 6632 (2/19)
Propylthiouracil (+)
Cefaclor (−)
Cefadroxil (−)
Cefamandole (−)
Cefatrizine (−)
Cefoperazone (−)
Ceforanide (−)
Cefotaxime (−)
Cefoxitin (−)
Ceftizoxime (−)
Cefuroxamine (−)
Cephalexin (−)
Cephalothin (−)
Cephapirin (−)
Cephradine (−)
Ciclopirox (−)
Fluoruracil (+) 
Piperacillin (−)
Riboflavin (−) Tetracylcine (+)
Carbimazole Frag 2184 (8/9)
Propylthiouracil (+) 
Methimzaole (+)
Carbimazole (+)
Amobarbital (+)
Fluorouracil (+)
Mephobarbital (+)
Metharbital (+)
Phenobarbital (+)
Butalbital (−)
Frag 6172 (4/4)
Propylthiouracil (+)
Carbimazole (+)
Methimazole (+)
Thioguanine (+)
Frag 6206 (4/4)
Propylthiouracil (+)
Carbimazole (+)
Methimazole (+)
Thioguanine (+)
Frag 6241 (4/4)
Propylthiouracil (+)
Carbimazole (+)
Methimazole (+)
Fluorouracil (+)
Frag 2182 (7/8)
Propylthiouracil (+)
Carbimazole (+)
Amobarbital (+)
Fluorouracil (+)
Mephobarbital (+)
Metharbital (+)
Phenobarbital (+)
Butalbital (−)
Frag 6229 (4/4)
Methimazole (+)
Carbimzaole (+)
Mephobarbital (+)
Metharbital (+)
Frag 6279 (3/18)
Methimazole (+)
Carbimazole (+)
Cefaclor (−)
Cefadroxil (−)
Cefamandole (−)
Cefatrizine (−)
Cefoperazone (−)
Ceforanide (−)
Cefotaxime (−)
Cefoxitin (−)
Ceftizoxime (−)
Cefuroxamine (−)
Cephalexin (−)
Cephalothin (−)
Cephradine (−)
Cetylpyridinium (−)
Cephapirin (−)
Cytarabine (+)
Frag 6298 (2/19)
Methimazole (+)
Carbimazole (+)
Cefaclor (−)
Cefadroxil (−)
Cefamandole (−)
Cefatrizine (−)
Cefoperazone (−)
Ceforanide (−)
Cefotaxime (−)
Cefoxitin (−)
Ceftizoxime (−)
Cefuroxamine (−)
Cephalexin (−)
Cephalothin (−)
Cephapirin (−)
Cytarabine (+)
Cetylpyridinium (−)
Naldixic acid (−)
Ranitidine (−)
Frag 6308 (3/18)
Carbimazole (+)
Cefaclor (−)
Cefadroxil (−)
Cefamandole (−)
Cefatrizine (−)
Cefoperazone (−)
Ceforanide (−)
Cefotaxime (−)
Cefoxitin (−)
Ceftizoxime (−)
Cefuroxamine (−)
Cephalexin (−)
Cephalothin (−)
Cephapirin (−)
Cephradine (−)
Cytarabine (+)
Ciclopirox (−)
Fluorouracil (+)
Figure 1: Cat-SAR fragments used for developmental toxicity predictions for propylthiouracil, methimazole, and carbimazole. Chemicals
in the developmental toxicity database contributing to each fragment are list along with the designation as a developmental toxicant (+) or
nontoxicant (−). Red fragments represent developmental toxicity and blue fragments represent nontoxicity.
The additional fragments associated with developmental
toxicity, 9479, 9564, and 9565, are found in a series of
tetracycline like antibiotics. Tetracycline is identiﬁed as a
developmental toxicant because of incorporation into teeth
and evidence of alteration in bone growth ([19], TERIS
MicroMedex accessed 06 July 2009); because of structural
similarity and mechanism of action the other tetracyclines
are also considered to be developmental toxicants.
There were 4 fragments which were found in molecules
thought not to be developmental toxicants: 6279, 6298,
6308, and 6332. The molecules these fragments were found
in are cephalosporin, antibiotics and across this class of
compounds there is evidence of the absence of risk for
developmental toxicity in both experimental animals and
humans ([19], TERIS MicroMedex accessed 06 July 2009).
The three antithyroid drugs analyzed represent the lim-
itedchoicesavailabletothehealthcareproviderwhoiscaring
for a woman with Graves’s disease during pregnancy. These
are old drugs, all available as generics; however despite their
long history of use there is little data on the developmental
risks resulting from use and exposure during pregnancy. All
threedrugsarecapableofcrossingtheplacentaandcancause
fetal goiter. Structural malformations are weakly associated
with MMI and CMI use during pregnancy. Thus while PTU
has been suggested to be without risk of developmental
toxicity in humans, that assumption appears to reﬂect a
shared attitude rather than presence of data demonstrating
developmental safety. An additional concern with the use
of PTU is liver toxicity leading to liver failure and need
for transplant [20]. Analysis of data submitted to the US
Food and Drug Administration (FDA) suggests that children
may be at increased risk for PTU-induced liver failure,
and cases have been observed of fetal hepatic toxicity in
women treated with PTU (FDA Adverse Events Reporting6 International Journal of Pediatric Endocrinology
System data obtained through the freedom of information
act). Additionally there have been cases of infants with
malformations observed in women treated with PTU, and
structuralmalformationshavebeenobservedinwomenwith
Graves’s disease who were not treated during pregnancy.
4. Conclusions
The choice of therapeutic strategies for hyperthyroidism
during pregnancy is limited. Surgery and radioiodine are
typically avoided, leaving propylthiouracil and methimazole
in the US [21]. CMI, a metabolic precursor of MMI, is
available in some countries outside of the US. In the US PTU
is recommended because of concern about developmental
toxicity from MMI [22] and CMI [23].
In summary the three drugs available to treat Graves’s
disease in pregnancy all appear, based on structural analysis,
to be capable of producing developmental toxicity. Given the
need to treat women with Graves’s disease during pregnancy
it is essential to develop new molecules with structural
attributes which provide suppression of thyroid function
while minimizing the risk for developmental toxicity. Based
on the results described herein, the cat-SAR method would
be a useful approach in screening compounds for develop-
mental toxicity as well as for investigating their therapeutic
and potential toxic mechanism of action.
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